MarketsandMarkets forecasts the metabolomics market to grow from USD 1.21 billion in 2016 to USD 2.38 billion by 2021, at a Compound Annual Growth Rate (CAGR) of 14.6% during the forecast period. Metabolomics plays a vital role in the fields of toxicity testing, biomarker development, drug discovery, and clinical diagnostics. Factors such as the growing demand for personalized medicine, increasing pharmaceutical and biotech R&D expenditure, and rising necessity for toxicology testing are driving the growth of the metabolomics market. Additionally, the potential for metabolomics to move beyond basic research and into the field of diagnostics, by integrating with other omics technologies such as proteomics and transcriptomics, is also supporting the growth of the metabolomics market during the forecast period.

By product & service, the metabolomics instruments segment is accounted for the largest share of the market

On the basis of products & services, the metabolomics market is segmented into metabolomics instruments and bioinformatics tools and services. In 2015, the metabolomics instruments segment commanded the largest share of the global metabolomics market. This is mainly due to the ability of these instruments to separate and detect the complex structure of metabolites on a large scale, providing quality results. Furthermore, wide usage of these instruments in research activities, increase in funds for research projects, development of innovative technologies in these tools, and their extensive application in the drug discovery process are fueling the growth of this market.

By application, the lung diffusion mixtures segment to accounted for the largest share of the market

Based on applications, the biomarker discovery segment accounted for the largest share of the global metabolomics market. The rising prevalence and incidence of chronic diseases such as cardiac diseases, cancer, and diabetes; growing acceptance of cancer diagnostic tests; and scientific progression in discovery technologies are major factors driving market growth in this segment.

By indication, the hospitals segment accounted for the largest share of the market

Based on indication, the cancer segment accounted for the largest share of the global metabolomics market, in 2015. The large share of this segment can be attributed to the increasing utility of biomarkers in patient stratification and the drug development process and increasing scientific progression in discovery technologies.

APAC to grow at the highest CAGR during the forecast period.

North America is expected to hold the largest market size in the metabolomics market during the forecast period, followed by the European region. On the other hand, the Asia Pacific market is expected to witness the highest growth during the forecast period. Growth in this region can be attributed to the huge demand for metabolomics in drug discovery and biomarker development experiments. Factors such as significant growth in the life science industry, increasing investments by global players over the past few years, and increasing number of tie-ups between manufacturers and institutions in this region are also expected to support market growth in this region.

Market Dynamics

Driver: Growing demand for personalized medicine

Personalized medicine is a technology-based and patient-centered customization of diagnosis and treatment evaluation. Recent developments in analytical technologies, such as the emergence of high-resolution mass spectrometry, have provided revolutionary analytical capabilities in metabolomics, offering the detection of more than 10,000 metabolites at a given point of time. Such developments are opening new opportunities for the utilization of metabolomics in the development of personalized and precision medicine. As metabolomics precisely differentiates between two or more disease phenotypes, it can be applied to identify metabolites and biomarkers related to the perturbation being investigated by providing detailed cellular information. These metabolites can be used to develop personalized prognostic, diagnostic, and treatment approaches for monitoring of disease progression, treatment efficacy, predisposition to drug-related side effects, and potential relapse. The growing focus on personalized medicine has driven the use of metabolomics tools by manufacturers engaged in developing rigorous strategies for understanding the root of a disease rather than simply treating a patient�s symptoms. Also, market players are also focusing on strategic collaborations and partnerships to augment the use of metabolomics in the field of personalized medicine. Moreover, pharmacometabonomics and pharmacokinetics are two new technologies concerned with the analysis of pre-dose metabolite profiles for predicting drug response prior to dosing. Considering such significant developments in the field of metabolomics, coupled with the increasing focus of industry participants to leverage the advantages of metabolomics approaches in the development of personalized medicine, the market is expected to witness significant growth in the coming years.

Restraint: Issues related to data examination and processing

Metabolomic techniques produce a very large volume of data as they create millions of data points per second over a ten-minute or longer analysis. Continuous growth in the generation of high-volume heterogeneous data is increasing data complexity, and it is becoming increasingly difficult to evaluate all these data points in an effective manner. Moreover, due to the chemical diversity of small molecule metabolites, it is impossible to study the entire metabolome using a single analytical technique. As a result, the data produced is not only complex but also leads to a proportionate increase in the demand for physical storage, correct and rigorous analysis, and suitable software/databases for visualization. Thus, the high complexity of data generated during life science research and the difficulty in managing it is hindering the growth of the metabolomics market.

Opportunity: Biomarker development

Metabolomics is used for the identification of new biomarkers through the use of bioinformatics tools, which indicate the changes in the physiological state of a cell or tissue. Biomarkers are important for the development of in vitro diagnostic tools, environmental toxicology screening methods, and drug discovery and development techniques. The omics revolution of the last decade has increased the application of metabolomics in biomedical research. As a result of these technological developments, new biomarkers are being regularly discovered. These biomarkers are required in medical sciences to better define and diagnose diseases, predict adverse drug events, and identify patient groups who would benefit from certain treatments. Moreover, in the near future, the identification of biomarkers related to the safety, sensitivity, and resistance to commercially available drugs will present significant growth opportunities for the metabolomics market.

Challenge: Complexity and diversity of biological samples

Omics technologies such as proteomics, genomics, and transcriptomics have well-established platforms to translate research findings into meaningful outcomes. However, in the study metabolites, the profiling of metabolomes is hampered by their diversity, variation of metabolite concentration, and their interdependence on complex biochemical factors. This creates several complications in standardizing any experiment. Moreover, designing protocols for sample preparation, identification, and standardization, and then translating results into meaningful data is a challenging task. As a result, currently, there is a growing need for improvements in both targeted and non-targeted metabolomics studies. However, the continuous developments in this field and growing number of R&D activities have the potential to provide the overall information on a complex biological network. This, in turn, can overcome the challenges posed by the complexity and diversity of biological samples in metabolomics.

Scope of the Report

Report Metric Details Market size available for years 2014�2021 Base year considered 2015 Forecast period 2016�2021 Forecast units Value (USD) Segments covered Product & Service, Application, Indication, and Region Geographies covered North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa Companies covered Agilent Technologies, Inc. (US), Bio- Rad Laboratories, Inc. (US), Bruker Corporation (US), Danaher Corporation (US), Thermo Fisher Scientific, Inc. (US), Waters Corporation (US), Shimadzu Corporation (Japan), LECO Corporation (US), Biocrates Life Sciences AG (Austria), Metabolon, Inc. (US), and Human Metabolome Technologies, Inc. (Japan)

The research report categorizes the metabolomics market to forecast the revenues and analyze the trends in each of the following sub-segments:

Global Metabolomics Market, by Product & Service

Metabolomic Instruments Separation Techniques Gas Chromatography (GC) Capillary Electrophoresis (CE) High-performance Liquid Chromatography (HPLC) Ultra-performance Liquid Chromatography (UPLC) Detection Techniques Nuclear Magnetic Resonance Spectroscopy (NMR) Mass Spectrometry (MS) Surface-based Mass Analysis

Metabolomic Bioinformatics Tools and Services Bioinformatics Tools & Database Bioinformatics Services



Global Metabolomics Market, by Application

Biomarker Discovery

Drug Discovery/Drug Assessment

Nutrigenomics

Toxicology Testing

Personalized Medicine

Functional Genomics

Other Applications

Global Metabolomics Market, by Indication

Cancer

Cardiovascular Disorders

Neurological disorders

Inborn Errors of Metabolism

Other Indications

Global Metabolomics Market, by Region

North America US Canada

Europe Germany France U.K. Italy Spain Russia Rest of Europe (RoE)

Asia-Pacific (APAC) Japan China India Rest of Asia-Pacific (RoAPAC)

Latin America Brazil Mexico Rest of Latin America (RoLA)

Middle East and Africa

Key Market Players

In 2015, Thermo Fisher Scientific accounted for the largest share of the global metabolomics market. Thermo Fisher provides a wide range of GC, LC, GC-MS, LC-MS, NMR spectrometer, and bioinformatics tools for metabolite analysis. The Analytical Technologies business segment of the company provides metabolomics solutions. The company has a strong presence in the US, which is the largest market for metabolomics. The company strategically invests in acquisitions, collaborations, and product innovations to increase its portfolio for mass spectrometry and chromatography.



Recent Developments

In December 2016, Shimadzu launched the NOA-7100 transportable NOx-O2 analyzer for quantifying nitrogen oxides (NOx) and oxygen (O2) concentration in real time. This launch enhanced the company�s portfolio.

In December 2016, Agilent Technologies collaborated with Transcriptic Inc. (U.S.), a robotic cloud-based biotechnology laboratory, to develop and provide rapid and efficient technologies for broad scale synthetic and discovery. This collaboration helped Agilent enhance its market position by serving a global customer base with automated and robotics workflows for bioreagent optimization.

In November 2016, Waters Corporation launched CORTECS T3 and CORTECS Shield RP18 column chemistries. These columns provide speed, selectivity, and sensitivity in UPLC, UHPLC, and HPLC separations. This launch expanded the company�s customer base for the CORTECS Columns product line.

In November 2016, Agilent Technologies opened a technology center in Folsom, California, U.S., for providing scientific consumables and supplies, especially chromatography consumables and hardware. This helped the company to offer productive, efficient, and high quality solutions to analytical laboratories.

In September 2016, Thermo Fisher Scientific opened its new global headquarters in Massachusetts, U.S. The facility helps the company to cater to a larger customer base.

Critical questions the report answers:

Where will all these developments take the industry in the long term?

What are the upcoming trends in the metabolomics market?

Which segment provides the most opportunity for growth?

Who are the leading vendors operating in this market?

What are the opportunities for new market entrants?

To speak to our analyst for a discussion on the above findings, click Speak to Analyst